Name | (3S)-1-Chloro-3-tosylamido-7-amino-2-heptanone hydrochloride |
---|---|
Synonyms |
MFCD00065395
EINECS 224-266-4 Benzenesulfonamide, N-[(1S)-5-amino-1-(2-chloroacetyl)pentyl]-4-methyl-, hydrochloride (1:1) N-[(3S)-7-Amino-1-chloro-2-oxoheptan-3-yl]-4-methylbenzenesulfonamide hydrochloride (1:1) Tosyllysine chloromethyl ketone (hydrochloride) N-[(3S)-7-Amino-1-chloro-2-oxo-3-heptanyl]-4-methylbenzenesulfonamide hydrochloride (1:1) |
Description | N-alpha-Tosyl-L-lysine chloromethyl ketone (TLCK), a trypsin like protease inhibitor, sensitizes HeLa cells to Fas-mediated cell death. |
---|---|
Related Catalog | |
In Vitro | N-alpha-Tosyl-L-lysine chloromethyl ketone exhibits an inhibitory effect on IFN-γ activities. The effect of TLCK is studied on the IFN-γ sensitization of HeLa cells towards cell death mediated by anti-Fas. Lower concentration of anti-Fas (10 ng/mL) are used to examine the interaction among the three effectors simultaneously, that is, anti-Fas, TLCK and IFN-γ. TLCK by itself up to 50 μM concentration exhibits a small decrease in cell viability. Beyond 50 μM, a dose dependent decrease in cell viability is observed. IFN-γ slightly reduces cell viability on its own. Addition of anti-Fas (10 ng/mL) results in a slight decrease in cell survival, which is enhanced more than additively in the presence of TLCK, most prominently between 50 and 100 μM. Upon addition of both anti-Fas and IFN-γ, a decrease (≈46%) in cell viability is observed. Moreover, the decrease in cell survival is further enhanced upon addition of higher concentrations of TLCK, 25 μM and more[1]. |
Cell Assay | HeLa cell line (human cervical cancer cells) is cultured in DMEM supplemented with 10% fetal bovine serum (FBS), L-glutamine (300 mg/L), penicillin (100 U/ml) and streptomycin(100 μg/ml) at 37°C in 5% CO2. HT-29 cell line (human colorectal adenocarcinoma) is cultured in RPMI supplemented with 10% fetal bovine serum (FBS), L-glutamine (300 mg/L), penicillin (100 U/mL) and streptomycin (100 μg/mL) at 37°C in 5% CO2. The cells are split every second day to keep the cell growth in logarithmic phase. The cells are routinely tested for mycoplasma. The cells are treated with different concentrations of TPCK or TLCK (5, 10, 25, 50, 100, 150, and 200 μM) for 30 min and/or with different concentrations of IFN-γ for 2 h followed by treatment with different concentrations of anti-Fas for 2 or 4 days for each specific experiment. The control cells are treated with the respective vehicle only. Cell viability analysis of HeLa and HT-29 cells is assessed by their XTT reduction activity. 100 µL of 2×104 cells/mL is incubated with treatments at the indicated time. At the end of the incubation period, 25 µL of 1 mg/mL XTT solution (containing 0.2 mM phenazine methosulphate (PMS) is added and the cells are incubated for an additional 1 h. The OD values are measured using an ELISA reader at 450 nm with a reference wavelength of 650 nm[1]. |
References |
Boiling Point | 509.8ºC at 760 mmHg |
---|---|
Melting Point | -165ºC (dec.) |
Molecular Formula | C14H22Cl2N2O3S |
Molecular Weight | 369.307 |
Flash Point | 262.1ºC |
Exact Mass | 368.072815 |
PSA | 97.64000 |
LogP | 4.55280 |
Storage condition | 2-8°C |
Water Solubility | H2O: 50 mg/mL |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
Symbol |
![]() GHS07 |
---|---|
Signal Word | Warning |
Hazard Statements | H315-H319-H335 |
Precautionary Statements | P261-P305 + P351 + P338 |
Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
Hazard Codes | Xi: Irritant; |
Risk Phrases | R36/37/38 |
Safety Phrases | 26-36 |
RIDADR | UN 3335 |
WGK Germany | 3 |
RTECS | XT5160000 |
HS Code | 29350090 |